WILMINGTON, MASSACHUSETTS--(CCNMatthews - March 9, 2006) - DUSA Pharmaceuticals, Inc.® (NASDAQ NMS:DUSA) reported today that DUSA’s Levulan® (aminolevulinic acid HCl, ALA) photodynamic therapy (PDT) was featured as one of 9 key topics highlighted by the AAD for the media during the recent American Academy of Dermatology (AAD) 2006 Annual Meeting held March 3-8 in San Francisco, CA. This meeting is widely considered to be the largest and most important dermatology conference of the year, with over 9000 dermatologists attending from the United States and around the world.
